PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2007 October; 8(4): 34–42.
Published online 2007 October 19. doi:  10.1208/pt0804085
PMCID: PMC2750671

Use of cyclodextrins as a cosmetic delivery system for fragrance materials: Linalool and benzyl acetate

Abstract

The aim of this study was to increase the stability and water solubility of fragrance materials, to provide controlled release of these compounds, and to convert these substances from liquid to powder form by preparing their inclusion complexes with cyclodextrins (CDs). For this purpose, linalool and benzyl acetate were chosen as the fragrance materials. The use of β-cyclodextrin (βCD) and 2-hydroxypropyl-β-cyclodextrin (2-HPβCD) for increasing the solubility of these 2 fragrance materials was studied. Linalool and benzyl acetate gave a B-type diagram with βCD, whereas they gave an AL-type diagram with 2-HPβCD. Therefore, complexes of fragrance materials with 2-HPβCD at 1:1 and 1:2 molar ratios (guest:host) were prepared. The formation of inclusion complexes was confirmed using proton nuclear magnetic resonance (1H-NMR) spectroscopy and circular dichroism spectroscopy. The results of the solubility studies showed that preparing the inclusion complex with 2-HPβCD at a 1:1 molar ratio increased the solubility of linalool 5.9-fold and that of benzyl acetate 4.2-fold, whereas the complexes at a 1:2 molar ratio increased the solubility 6.4- and 4.5-fold for linalool and benzyl acetate, respectively. The stability and in vitro release studies were performed on the gel formulations prepared using uncomplexed fragrance materials or inclusion complexes of fragrance materials at a 1:1 molar ratio. It was observed that the volatility of both fragrance materials was decreased by preparing the inclusion complexes with 2-HPβCD. Also, in vitro release data indicated that controlled release of fragrances could be possible if inclusion complexes were prepared.

Keywords: Cyclodextrin, benzyl acetate, linalool, solubility, stability, controlled release, inclusion complex

Full Text

The Full Text of this article is available as a PDF (310K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Healy LL. Gelled emollient systems for controlled fragrance release and enhanced product performance. Cosmet Toilet. 2002;117:47–54.
2. Matsuda H, Ito K, Fujiwara Y, et al. Complexation of various fragrance materials with 2-hydroxypropyl-β-cyclodextrin. Chem Pharm Bull (Tokyo) 1991;39:827–830.
3. Tanaka M, Matsuda H, Sumiyoshi H, et al. 2-Hydroxypropylated cyclodextrins as a sustained release carrier for fragrance materials. Chem Pharm Bull (Tokyo) 1996;44:416–420.
4. Amann M, Dressnandt G. Solving problems with cyclodextrins in cosmetics. Cosmet Toilet. 1993;108:90–95.
5. Loftsson T. Cyclodextrins in skin delivery. Cosmet Toilet. 2000;115:59–66.
6. Del Valle EMM. Cyclodextrins and their uses: a review. Process Biochem. 2004;39:1033–1046. doi: 10.1016/S0032-9592(03)00258-9. [Cross Ref]
7. Motwani M, Zatz JL. Applications of cyclodextrins in skin products. Cosmet Toilet. 1997;112:39–47.
8. Loftsson T, Másson M. Cyclodextrins in topical drug formulations: theory and practice. Int J Pharm. 2001;225:15–30. doi: 10.1016/S0378-5173(01)00761-X. [PubMed] [Cross Ref]
9. Másson M, Loftsson T, Másson G, Stefánsson E. Cyclodextrins as permeation enhancers: some theoretical evaluations and in vitro testing. J Control Release. 1999;59:107–118. doi: 10.1016/S0168-3659(98)00182-5. [PubMed] [Cross Ref]
10. Loftsson T, Ólafsdóttir BJ, Bodor N. The effects of cyclodextrins on transdermal delivery of drugs. Eur J Pharm Biopharm. 1991;37:30–33.
11. Rogers K. Controlled release technology and delivery systems. Cosmet Toilet. 1999;114:53–60.
12. Buschmann HJ, Schollmeyer E. Applications of cyclodextrins in cosmetic products: a review. J Cosmet Sci. 2002;53:185–191. [PubMed]
13. Duchene D, Wouessıdjewe D. Physicochemical characteristics and pharmaceutical uses of cyclodextrin derivatives, Part I. Pharm Technol. 1990;14:26–34.
14. Çelebi N, Kışlal Ö, Tarımcı N. The effect of β-cyclodextrin and penetration additives on the release of naproxen from ointment bases. Pharmazie. 1993;48:914–917.
15. Anadolu RY, Sen T, Tarımcı N, Birol A, Erdem C. Improved efficacy and tolerability of retinoic acid in acne vulgaris: a new topical formulation with cyclodextrin complex. J Eur Acad Dermatol Venereol. 2004;18:416–421. doi: 10.1111/j.1468-3083.2004.00929.x. [PubMed] [Cross Ref]
16. Matsuda H, Ito K, Taki A, Uejima O, inventors. Shiseido Company Ltd., assignee. Cosmetic composition containing inclusion product with hydroxyalkylated cyclodextrin. US patent 5 447 920. September 5, 1995.
17. Higuchi T, Connors KA. Phase-solubility techniques. Adv Anal Chem Instrum. 1965;4:117–210.
18. Ajısaka N, Hara K, Mikuni K, Hara K, Hashimoto H. Effects of branched cyclodextrins on the solubility and stability of terpenes. Biosci Biotechnol Biochem. 2000;64:731–734. doi: 10.1271/bbb.64.731. [PubMed] [Cross Ref]
19. Lu CS, Hu CJ, Yu Y, Meng QJ. The inclusion compounds of β-cyclodextrin with 4-substituted benzoic acid and benzaldehyde drugs studied by proton nuclear magnetic resonance spectroscopy. Chem Pharm Bull (Tokyo) 2000;48:56–59. [PubMed]
20. Choi HS, Knevel AM, Chang C. Molecular complexation: β-cyclodextrin and benzaldehyde inclusion complex. Pharm Res. 1992;9:690–693. doi: 10.1023/A:1015870631120. [PubMed] [Cross Ref]
21. Anguıano-Igea S, Otero-Espınar FJ, Vıla-Jato JL, Blanco-Mendez J. Interaction of clofibrate with cyclodextrin in solution: phase solubility1H NMR and molecular modelling studies. Eur J Pharm Sci. 1997;5:215–221. doi: 10.1016/S0928-0987(97)00277-7. [Cross Ref]
22. Frank SG. Inclusion compounds. J Pharm Sci. 1975;64:1585–1604. doi: 10.1002/jps.2600641003. [PubMed] [Cross Ref]
23. Szejtli J. Cyclodextrin Technology. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1988.
24. Bekers O, Uıjtendaal EV, Beıjnen JH, Bult A, Underberg WJM. Cyclodextrins in the pharmaceutical field. Drug Dev Ind Pharm. 1991;17:1503–1549. doi: 10.3109/03639049109026630. [Cross Ref]
25. Duchene D, Wouessidjewe D, Poelman MC. Dermal uses of cyclodextrins and derivatives. In: Duchêne D, editor. New Trends in Cyclodextrins and Derivatives. Paris, France: Editions de Sante; 1991. pp. 302–302.
26. Frömming KH, Szejtli J. Cyclodextrins in Pharmacy. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1994.

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists